Indian drugmaker Zydus Cadila, part of Cadila Healthcare (BOM: 532321), has applied for an Indian Emergency Use Authorization (EUA) for ZyCoV-D, a plasmid DNA vaccine against COVID-19.
The submission is based on the largest clinical trial for its COVID-19 vaccine so far, which took place in over 50 centers in India, and included the adolescent population.
While the vaccine has the disadvantage that it must be administered in three separate doses, the firm is evaluating a less burdensome two-dose regimen.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze